AU2008251692B2 - P70 S6 kinase inhibitors - Google Patents

P70 S6 kinase inhibitors Download PDF

Info

Publication number
AU2008251692B2
AU2008251692B2 AU2008251692A AU2008251692A AU2008251692B2 AU 2008251692 B2 AU2008251692 B2 AU 2008251692B2 AU 2008251692 A AU2008251692 A AU 2008251692A AU 2008251692 A AU2008251692 A AU 2008251692A AU 2008251692 B2 AU2008251692 B2 AU 2008251692B2
Authority
AU
Australia
Prior art keywords
phenyl
imidazol
trifluoromethyl
compound
piperidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2008251692A
Other languages
English (en)
Other versions
AU2008251692A1 (en
Inventor
Robert Dean Dally
Christian L. Holst
Jianping Huang
Sajan Joseph
Timothy Alan Shepherd
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of AU2008251692A1 publication Critical patent/AU2008251692A1/en
Application granted granted Critical
Publication of AU2008251692B2 publication Critical patent/AU2008251692B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2008251692A 2007-05-11 2008-05-01 P70 S6 kinase inhibitors Ceased AU2008251692B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US91733107P 2007-05-11 2007-05-11
US60/917,331 2007-05-11
PCT/US2008/062143 WO2008140947A1 (en) 2007-05-11 2008-05-01 P70 s6 kinase inhibitors

Publications (2)

Publication Number Publication Date
AU2008251692A1 AU2008251692A1 (en) 2008-11-20
AU2008251692B2 true AU2008251692B2 (en) 2012-10-11

Family

ID=39765082

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008251692A Ceased AU2008251692B2 (en) 2007-05-11 2008-05-01 P70 S6 kinase inhibitors

Country Status (33)

Country Link
US (2) US8093383B2 (OSRAM)
EP (1) EP2148880B1 (OSRAM)
JP (1) JP5503532B2 (OSRAM)
KR (1) KR101088219B1 (OSRAM)
CN (1) CN101679439B (OSRAM)
AR (1) AR066344A1 (OSRAM)
AU (1) AU2008251692B2 (OSRAM)
BR (1) BRPI0811212A2 (OSRAM)
CA (1) CA2687265C (OSRAM)
CL (1) CL2008001230A1 (OSRAM)
CO (1) CO6241109A2 (OSRAM)
CR (1) CR11106A (OSRAM)
DK (1) DK2148880T3 (OSRAM)
DO (1) DOP2009000257A (OSRAM)
EA (1) EA016445B1 (OSRAM)
EC (1) ECSP099721A (OSRAM)
ES (1) ES2483726T3 (OSRAM)
GT (1) GT200900292A (OSRAM)
HR (1) HRP20140611T1 (OSRAM)
IL (1) IL201564A (OSRAM)
MA (1) MA31433B1 (OSRAM)
MX (1) MX2009012075A (OSRAM)
MY (1) MY154898A (OSRAM)
NZ (1) NZ580423A (OSRAM)
PE (1) PE20090887A1 (OSRAM)
PL (1) PL2148880T3 (OSRAM)
PT (1) PT2148880E (OSRAM)
RS (1) RS53451B (OSRAM)
SI (1) SI2148880T1 (OSRAM)
TN (1) TN2009000446A1 (OSRAM)
TW (1) TWI423805B (OSRAM)
UA (1) UA99284C2 (OSRAM)
WO (1) WO2008140947A1 (OSRAM)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA99284C2 (ru) * 2007-05-11 2012-08-10 Елі Ліллі Енд Компані ИНГИБИТОРЫ р70 S6-КИНАЗЫ
US8252791B2 (en) * 2008-08-13 2012-08-28 Jenrin Discovery, Inc. Purine compounds as cannabinoid receptor blockers
WO2010056574A1 (en) * 2008-11-11 2010-05-20 Eli Lilly And Company P70 s6 kinase inhibitor and mtor inhibitor combination therapy
AR074072A1 (es) 2008-11-11 2010-12-22 Lilly Co Eli Compuesto de imidazol -piperidin -pirrol-pirimidin-6-ona, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para tratar el glioblastoma multiforme
US8334293B2 (en) 2008-11-11 2012-12-18 Eli Lilly And Company P70 S6 kinase inhibitor and EGFR inhibitor combination therapy
CA2751886C (en) 2009-02-11 2017-08-29 Merck Patent Gmbh Novel amino azaheterocyclic carboxamides
WO2011017009A1 (en) 2009-08-07 2011-02-10 Merck Patent Gmbh Novel azaheterocyclic compounds
WO2011050016A1 (en) * 2009-10-23 2011-04-28 Eli Lilly And Company Akt inhibitors
MX2012009030A (es) 2010-02-03 2012-09-12 Signal Pharm Llc Identificacion de mutacion lkb1 como biomarcador predictivo para sensibilidad a inhibidores de tor cinasa.
EP2598497B1 (en) 2010-07-29 2019-03-06 Merck Patent GmbH Cyclic amine azaheterocyclic carboxamides
UA110113C2 (xx) 2010-07-29 2015-11-25 Біциклічні азагетероциклічні карбоксаміди
EP2643313B9 (en) 2010-11-24 2017-02-22 Merck Patent GmbH Quinazoline carboxamide azetidines
CN106946796B (zh) 2011-09-12 2020-05-08 默克专利有限公司 用作激酶活性调节剂的氨基嘧啶衍生物
MX346095B (es) 2011-09-12 2017-03-07 Merck Patent Gmbh Nuevas imidazol-aminas como moduladores de la actividad de cinasas.
AU2013312477B2 (en) * 2012-09-06 2018-05-31 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
WO2014078634A1 (en) * 2012-11-16 2014-05-22 Merck Patent Gmbh Novel imidazol-piperidinyl derivatives as modulators of kinase activity
AR093512A1 (es) 2012-11-16 2015-06-10 Merck Patent Gmbh Derivados heterociclicos como moduladores de la actividad de cinasas
PE20151782A1 (es) 2012-11-29 2015-12-02 Merck Patent Gmbh Derivados de azaquinolin-carboxamida
SG10201900954SA (en) * 2013-03-11 2019-02-27 Merck Patent Gmbh Heterocycles as Modulators of Kinase Activity
MX374749B (es) 2013-04-17 2025-03-06 Signal Pharm Llc Terapia de combinacion que comprende un inhibidor de tor cinasa y un analogo de citidina para tratar cancer.
NZ629230A (en) 2013-04-17 2017-05-26 Signal Pharm Llc Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one
NZ629332A (en) 2013-04-17 2017-05-26 Signal Pharm Llc Treatment of cancer with dihydropyrazino-pyrazines
CA2909579A1 (en) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Combination therapy comprising a tor kinase inhibitor and n-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide for treating cancer
EP2986322A1 (en) 2013-04-17 2016-02-24 Signal Pharmaceuticals, LLC Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer
NZ629411A (en) 2013-04-17 2017-06-30 Signal Pharm Llc Treatment of cancer with dihydropyrazino-pyrazines
NZ629469A (en) 2013-04-17 2017-05-26 Signal Pharm Llc Methods for treating cancer using dihydropyrazino-pyrazine compound combination therapy
HK1223286A1 (zh) 2013-05-29 2017-07-28 西格诺药品有限公司 7-(6-(2-羟基丙-2-基)吡啶-3-基)-1-((反式)-4-甲氧基环己基)-3,4-二氢吡嗪并[2,3-b]吡嗪-2(1h)-酮的药物组合物、其固体形式及它们的使用方法
WO2015134536A1 (en) * 2014-03-04 2015-09-11 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
US9980966B2 (en) 2014-04-03 2018-05-29 Merck Patent Gmbh Combinations of cancer therapeutics
EP3131551A4 (en) 2014-04-16 2017-09-20 Signal Pharmaceuticals, LLC SOLID FORMS COMPRISING 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL) PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO(2,3-b)PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
NZ714742A (en) 2014-04-16 2017-04-28 Signal Pharm Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
WO2016040078A1 (en) * 2014-09-10 2016-03-17 Eli Lilly And Company Substituted phenyl imidazolyl piperidyl compounds as p70s6k1 inhibitors
WO2016164641A1 (en) 2015-04-08 2016-10-13 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
CN106187899B (zh) * 2016-06-28 2019-07-16 绍兴文理学院 一种氟代氮杂芳烃的合成方法
MY198676A (en) 2017-06-22 2023-09-15 Celgene Corp Treatment of hepatocellular carcinoma characterized by hepatitis b virus infection
WO2022101459A1 (en) 2020-11-16 2022-05-19 Merck Patent Gmbh Kinase inhibitor combinations for cancer treatment

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005117909A2 (en) * 2004-04-23 2005-12-15 Exelixis, Inc. Kinase modulators and methods of use
WO2008075109A1 (en) * 2006-12-21 2008-06-26 Astex Therapeutics Limited Substituted piperidines having protein kinase inhibiting activity

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL1004346C2 (nl) 1996-10-23 1998-04-24 Dsm Nv Werkwijze voor het scheiden van een mengsel van enantiomeren in een geschikt oplosmiddel.
PA8474101A1 (es) 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
MY179032A (en) 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
ATE543821T1 (de) 2004-12-28 2012-02-15 Exelixis Inc Ä1h-pyrazoloä3,4-düpyrimidin-4-ylü-piperidin- oder piperazinverbindungen als serin-threonin- kinasemodulatoren (p70s6k, atk1 und atk2) zur behandlung von immunologischen, entzündlichen und proliferativen erkrankungen
US20090325924A1 (en) 2005-06-30 2009-12-31 Stuart Edward GPCR Agonists
JP2009536620A (ja) 2006-04-25 2009-10-15 アステックス、セラピューティックス、リミテッド 医薬組み合わせ物
US8796293B2 (en) 2006-04-25 2014-08-05 Astex Therapeutics Limited Purine and deazapurine derivatives as pharmaceutical compounds
WO2008012635A2 (en) 2006-07-26 2008-01-31 Pfizer Products Inc. Amine derivatives useful as anticancer agents
UA99284C2 (ru) * 2007-05-11 2012-08-10 Елі Ліллі Енд Компані ИНГИБИТОРЫ р70 S6-КИНАЗЫ

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005117909A2 (en) * 2004-04-23 2005-12-15 Exelixis, Inc. Kinase modulators and methods of use
WO2008075109A1 (en) * 2006-12-21 2008-06-26 Astex Therapeutics Limited Substituted piperidines having protein kinase inhibiting activity

Also Published As

Publication number Publication date
JP2010526814A (ja) 2010-08-05
PT2148880E (pt) 2014-08-28
TW200848053A (en) 2008-12-16
EP2148880B1 (en) 2014-05-28
AR066344A1 (es) 2009-08-12
PL2148880T3 (pl) 2014-10-31
PE20090887A1 (es) 2009-07-13
EA016445B1 (ru) 2012-05-30
CO6241109A2 (es) 2011-01-20
MY154898A (en) 2015-08-28
IL201564A (en) 2014-08-31
SI2148880T1 (sl) 2014-07-31
CA2687265C (en) 2012-12-04
HK1140767A1 (en) 2010-10-22
EP2148880A1 (en) 2010-02-03
RS53451B (sr) 2014-12-31
DOP2009000257A (es) 2010-03-31
WO2008140947A1 (en) 2008-11-20
CN101679439B (zh) 2013-09-11
MA31433B1 (fr) 2010-06-01
CR11106A (es) 2010-04-12
US20120071490A1 (en) 2012-03-22
CL2008001230A1 (es) 2009-05-22
TN2009000446A1 (en) 2011-03-31
CN101679439A (zh) 2010-03-24
CA2687265A1 (en) 2008-11-20
KR101088219B1 (ko) 2011-11-30
MX2009012075A (es) 2009-11-19
KR20100005710A (ko) 2010-01-15
BRPI0811212A2 (pt) 2014-10-29
AU2008251692A1 (en) 2008-11-20
US8093383B2 (en) 2012-01-10
TWI423805B (zh) 2014-01-21
HRP20140611T1 (hr) 2014-08-15
JP5503532B2 (ja) 2014-05-28
DK2148880T3 (da) 2014-06-16
US20090163714A1 (en) 2009-06-25
NZ580423A (en) 2012-02-24
IL201564A0 (en) 2010-05-31
ECSP099721A (es) 2009-12-28
GT200900292A (es) 2011-06-24
UA99284C2 (ru) 2012-08-10
EA200971051A1 (ru) 2010-06-30
ES2483726T3 (es) 2014-08-07

Similar Documents

Publication Publication Date Title
AU2008251692B2 (en) P70 S6 kinase inhibitors
ES2391704T3 (es) Inhibidores de cinasa AKT y P70 S6
EP3354652B1 (en) Piperidin-4-yl azetidine derivatives as jak1 inhibitors
AU2010310786B2 (en) AKT inhibitors
TW201906848A (zh) 化學化合物
CA3122136A1 (en) Tyrosine kinase inhibitors, compositions and methods there of
HK1140767B (en) P70 s6 kinase inhibitors
HK1158203B (en) Akt and p70 s6 kinase inhibitors

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired